Xilin Li Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Scientist
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Xilin Li's research investigates the genotoxicity and mutagenicity of various chemical compounds, with a particular focus on nitrosamine impurities in drug substances. Utilizing human cell lines, such as TK6 and HepaRG models, Li evaluates the potential DNA damage and mutagenic effects of these impurities. This work has involved the development and application of methods to assess genotoxicity in both 2D and 3D cell culture systems. Additionally, Li's research extends to the metabolism and toxicity of compounds like cannabidiol, examining its transcriptomic profiles in human and mouse cells. Further studies explore the mechanisms of somatic cell mutation accumulation and the relationship between nonsteroidal anti-inflammatory drug use and pancreatic cancer risk. Li has authored 15 publications and has a h-index of 4, with recent work published in 2025.
Metrics
- h-index: 15
- Publications: 28
- Citations: 485
Selected Publications
-
Comparative genotoxicity assessment of ortho-phthalaldehyde using human in vitro organotypic airway epithelial cultures and standard in vitro genotoxicity assays (2026)
-
Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing (2025)
-
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cell models (2025)
-
Potential anticancer effects and toxicity of flavones luteolin and apigenin <i>in vivo</i> (2025)
-
Review of black cohosh-induced toxicity and adverse clinical effects (2025)
-
Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing (2025)
-
7-Hydroxycannabidiol and 7-carboxycannabidiol induced cytotoxicity via apoptosis and endoplasmic reticulum stress in human hepatic cells (2025)
-
Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells (2025)
-
Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells (2024)
-
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test (2024)
-
Investigation of cannabidiol-induced cytotoxicity in human hepatic cells (2024)
-
Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations (2024)
-
Metabolism and liver toxicity of cannabidiol (2024)
-
Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells (2024)
-
Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing (2024)
Collaboration Network
Top Collaborators
- Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
- Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells
- Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cell models
- Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing
- Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations
Showing 5 of 8 shared publications
- Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
- Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells
- Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cell models
- Review of black cohosh-induced toxicity and adverse clinical effects
- Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing
- Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
- Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells
- Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations
- Review of black cohosh-induced toxicity and adverse clinical effects
- Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
- Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells
- Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cell models
- Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations
- Metabolism and liver toxicity of cannabidiol
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
- Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing
- Potential anticancer effects and toxicity of flavones luteolin and apigenin <i>in vivo</i>
- Metabolism and liver toxicity of cannabidiol
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
- Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing
- Potential anticancer effects and toxicity of flavones luteolin and apigenin <i>in vivo</i>
- Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
- Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing
- Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing
- Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
- Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells
- Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cell models
Similar Researchers
Based on overlapping research topics